Karuna Therapeutics has licensed two small molecules that shuttering Goldfinch Bio had developed for kidney disorders. These compounds target a pathway that could also treat neurological disorders, giving clinical-stage Karuna the opportunity to compete against a drug candidate from Boehringer Ingelheim.
There’s a serious dearth of psychiatric drugs under development, but Janssen is taking a gander at speeding up innovation on that front. The project’s called Neuroscience Catalyst. Over the course of three years, Janssen and Johnson & Johnson Innovation plan to set up 10 research projects that examine mood disorders, Alzheimer’s disease and other neurological conditions. Working […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Miranda Dale had her first breakdown during her freshman year at the University of Virginia in Charlottesville. It was 2 a.m. on a Saturday, and she hadn't left her dorm room in days. "I honestly didn't know what to do," says Dale. "I heard rumors that...